Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | Arthritis Research & Therapy

Figure 3

From: Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome

Figure 3

Reduction of mRNA expression of HEV genes and chemokines by LTBR-Ig. Real-time PCR analysis was performed on total mRNA isolated from lacrimal glands and lymph nodes from mice after treatment from 10 to 20 weeks with LTBR-Ig or MOPC-21. There were eight mice in each treatment group. The fold-change for each gene shown here was calculated relative to expression of that gene in healthy lacrimal glands from 20-week-old female NOD mice (n = 8). A comparison is shown of the effect of each treatment type on genes associated with HEV (a); adhesion molecules VCAM and MAdCAM (b); homeostatic chemokines (c); and other chemokines (d). The mean fold-change of eight samples and the standard deviation are plotted. Statistical analysis was by Student's T-test; P*< 0.05; P**< 0.01; P***< 0.001. HEV, high endothelial venule; LTBR-Ig; lymphotoxin-beta receptor-mouse immunoglobulin (Fc) chimeric inhibitor; MAdCAM, mucosal adressin/cell adhesion molecule; NOD, non-obese diabetic; PCR, polymerase chain reaction; VCAM, vascular cell adhesion molecule.

Back to article page